for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jazz Pharmaceuticals PLC

JAZZ.OQ

Latest Trade

133.22USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

127.84

 - 

188.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
133.22
Open
--
Volume
--
3M AVG Volume
14.08
Today's High
--
Today's Low
--
52 Week High
188.70
52 Week Low
127.84
Shares Out (MIL)
61.36
Market Cap (MIL)
8,174.91
Forward P/E
9.20
Dividend (Yield %)
--

Next Event

Jazz Pharmaceuticals PLC Extraordinary Shareholders Meeting

Latest Developments

More

Jazz Pharmaceuticals Announces U.S. FDA Approval Of Xywav Oral Solution For Idiopathic Hypersomnia In Adults

Jazz Pharma Reports Q2 2021 Financial Results

Jazz Pharmaceuticals Says 2021 Total Revenue Guidance Increased To Range Of $3.02 Billion To $3.18 Billion

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Industry

Biotechnology & Drugs

Contact Info

Fifth Fl

Waterloo Exchange, Waterloo Road

4

Ireland

+353.1.6347800

https://www.jazzpharma.com/

Executive Leadership

Bruce C. Cozadd

Chairman of the Board, Chief Executive Officer

Daniel N. Swisher

President

Renee D. Gala

Chief Financial Officer, Executive Vice President

Christopher John Tovey

Chief Operating Officer, Executive Vice President, Managing Director - Europe & International

Kimberly Sablich

Executive Vice President, General Manager - North America

Key Stats

1.76 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.9K

2019

2.2K

2020

2.4K

2021(E)

3.1K
EPS (USD)

2018

13.700

2019

16.230

2020

12.460

2021(E)

14.492
Price To Earnings (TTM)
141.09
Price To Sales (TTM)
3.11
Price To Book (MRQ)
1.97
Price To Cash Flow (TTM)
20.47
Total Debt To Equity (MRQ)
163.24
LT Debt To Equity (MRQ)
157.22
Return on Investment (TTM)
0.40
Return on Equity (TTM)
0.37

Latest News

Latest News

U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav

Jazz Pharmaceuticals PLC said on Thursday its sleep disorder drug Xywav received U.S. regulatory approval for the expanded use in patients suffering from excessive daytime sleepiness despite a good night's sleep.

U.S. FDA approves Jazz Pharma's drug for excessive daytime sleepiness

Jazz Pharmaceuticals PLC said on Thursday the U.S. Food and Drug Administration has approved its sleep disorder drug Xywav for expanded use in patients suffering from excessive daytime sleepiness despite a good night's sleep.

Jazz Pharma to buy GW Pharma in $7.2 bln deal

Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a cash-and-stock deal worth $7.2 billion. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shailesh Kuber)

PharmaMar shares jump after solid lung cancer drug results

Shares in PharmaMar rose more than 7% in early trade on Monday after the Spanish pharmaceutical firm and its U.S. partner Jazz Pharmaceuticals reported positive results from a trial of their Zepzelca drug to treat lung cancer.

Pharma Mar posts 131 million euro nine-month net profit thanks to Jazz Pharma agreement

Spanish biotech Pharma Mar <PHMR.MC> booked a 131 million euro ($152.84 million) net profit in the first nine months of the year thanks to a payment from drug maker Jazz Pharmaceuticals <JAZZ.O> to market a drug in Canada, Pharma Mar said on Tuesday.

BRIEF-Pharma Mar Receives Payment Of 100 Mln Dollars From Jazz Pharmaceuticals For Lurbinectedin US Approval

* RECEIVES PAYMENT OF 100 MILLION DOLLARS FROM JAZZ PHARMACEUTICALS FOR APPROVAL OF LURBINECTEDIN IN U.S. AS TREATMENT FOR METASTATIC SMALL CELL LUNG CANCER

BRIEF-Pharma Mar: US FDA Approves Lurbinectedin To Treat Metastatic Small Cell Lung Cancer

* SAID ON MONDAY, ALONG WITH JAZZ PHARMACEUTICALS PLC, THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAD APPROVED ZEPZELCA (LURBINECTEDIN) FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION, AFTER PLATINUM-BASED...

BRIEF-Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval Of Zepzelca For Treatment Of Metastatic Small Cell Lung Cancer

* JAZZ PHARMACEUTICALS ANNOUNCES U.S. FDA ACCELERATED APPROVAL OF ZEPZELCA™ (LURBINECTEDIN) FOR THE TREATMENT OF METASTATIC SMALL CELL LUNG CANCER

BRIEF-Jazz Pharma Prices Private Offering Of $850 Mln Of 2.000% Exchangeable Senior Notes Due 2026

* JAZZ PHARMACEUTICALS ANNOUNCES PRICING OF PRIVATE OFFERING OF $850 MILLION OF 2.000% EXCHANGEABLE SENIOR NOTES DUE 2026 Source text for Eikon: Further company coverage:

BRIEF-Jazz Pharma - Private Offering Of $850 Mln Exchangeable Senior Notes Due 2026

* JAZZ PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF $850 MILLION OF EXCHANGEABLE SENIOR NOTES DUE 2026

BRIEF-Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Jazz Pharma Reports Q1 Diluted EPS Loss 2.82 USD Vs 1.47 USD Profit Year Ago

* Q1 DILUTED EPS LOSS 2.82 USD VERSUS 1.47 USD PROFIT YEAR AGO

BRIEF-Jazz Pharma Stops Enrollment In Phase 3 Study Evaluating Defibrotide For Prevention Of Veno-Occlusive Disease

* JAZZ PHARMACEUTICALS STOPS ENROLLMENT IN PHASE 3 STUDY EVALUATING DEFIBROTIDE FOR PREVENTION OF VENO-OCCLUSIVE DISEASE

BRIEF-Jazz Pharma Says Porton Biopharma Entered Into New Agreement With New Partner To Commercialize & Distribute Erwinaze

* JAZZ PHARMACEUTICALS - PORTON BIOPHARMA LIMITED ENTERED INTO NEW AGREEMENT WITH NEW PARTNER TO COMMERCIALIZE & DISTRIBUTE ERWINAZE

BRIEF-Jazz Pharmaceuticals Sees A Limited Financial Impact From COVID-19

* JAZZ PHARMACEUTICALS PLC - SEES A LIMITED FINANCIAL IMPACT FROM COVID-19

BRIEF-Jazz Pharmaceuticals - PDUFA Goal Date For An FDA Decision For Jzp-258 Is July 21, 2020

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR JZP-258 FOR CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

Jazz Pharma's sleep disorder drug gets European panel backing

Jazz Pharmaceuticals Plc's treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency (EMA), the regulator said on Friday.

BRIEF-Jazz Pharma's sleep disorder drug gets European panel backing

* EMA - CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR ISTURISA (OSILODROSTAT) FOR THE TREATMENT OF CUSHING’S SYNDROME

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up